Venus Remedies secures marketing approval from Israel, Colombia for two oncology drugs

The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia

Astellas completes acquisition of Propella Therapeutics

Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer

AstraZeneca Pharma India receives permission to Import formulations of new drug for sale

The receipt of this permission paves way for the launch of Olaparib film coated tablets in India

Asia Healthcare Holdings takes majority stake in Asian Institute of Nephrology and Urology

AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

Elekta Unity MR Linac revolutionizes cancer care in India

Pfizer acquires Seagen for US$ 43 billion to battle cancer

Proposed combination enhances Pfizer’s position as a leading company in oncology

Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC

AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.

Alembic gets USFDA final approval for ANDA Docetaxel Injection

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI